Trump admin revises 340B rebate pilot, angering hospitals
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Trump administration revised terms of a rebate pilot for the 340B Drug Pricing Program, letting drugmakers offer "timely" rebates rather than upfront discounts to certain hospitals and clinics.
- The revised pilot is slated to take effect Jan. 1, 2027, and targets specific drugs and pharmaceutical companies involved in the first two rounds of the Medicare Drug Price Negotiation Program.
- Tom Engels, head of the Health Resources and Services Administration, framed the change as modernizing oversight and preserving the program's "long-term sustainability" for patients and communities.
- The revision is described as controversial and is angering hospitals, with the shift potentially transforming a core tenet of the 340B program.
Why it matters: Hospitals depend on 340B upfront discounts to fund care for low-income patients, so swapping those for delayed rebates shifts timing risk to safety-net providers. The pilot also targets drugs already subject to Medicare price negotiations, layering two pricing experiments on the same products starting in 2027.
